Cardio Diagnostics Holdings (CDIO) Accounts Payables (2021 - 2026)
Cardio Diagnostics Holdings (CDIO) posted Accounts Payables of $122970.0 for Q1 2026, up 26.2% sequentially from $97442.0 in Q4 2025, and up 13.67% YoY from $108181.0 in Q1 2025.
Cardio Diagnostics Holdings (CDIO) Accounts Payables (2021 - 2026) Analysis & Trends
Cardio Diagnostics Holdings has reported Accounts Payables for 6 years, with the latest figure at $122970.0 in Q1 2026.
- Quarterly Accounts Payables rose 13.67% year-over-year to $122970.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $122970.0 (up 13.67% YoY) and the FY2025 annual result came in at $97442.0, up 11.16% from the prior year.
- Accounts Payables climbed to $122970.0 in Q1 2026 per CDIO's latest filing, from $97442.0 in the prior quarter.
- Over five years, Accounts Payables peaked at $1.1 million in Q4 2022 and troughed at $48724.0 in Q2 2025.
- A 5-year average of $309028.3 and a median of $136852.0 in 2025 frame the typical range for Accounts Payables.
- The sharpest annual moves came in 2022 and 2024: Accounts Payables surged 3142.55% in 2022, then tumbled 92.0% in 2024.
- Over 5 years, Accounts Payables stood at $1.1 million in 2022, then sank by 77.86% to $243213.0 in 2023, then plunged by 63.96% to $87661.0 in 2024, then gained by 11.16% to $97442.0 in 2025, then rose by 26.2% to $122970.0 in 2026.
- According to Business Quant data, Accounts Payables over the past three periods registered $122970.0, $97442.0, and $150734.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.59 Bn | 131.73 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.21 Bn | 78.22 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.65 Bn | 60.47 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 35.57 Mn |
| 10 | Cardio Diagnostics Holdings | 6.14 Mn | 554,201.32 | - | 130,082.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 130,082.00 |
| Mar 31, 2026 | 122,970.00 |
| Dec 31, 2025 | 97,442.00 |
| Sep 30, 2025 | 150,734.00 |
| Jun 30, 2025 | 48,724.00 |
| Mar 31, 2025 | 108,181.00 |
| Dec 31, 2024 | 87,661.00 |
| Sep 30, 2024 | 74,808.00 |
| Jun 30, 2024 | 52,081.00 |
| Mar 31, 2024 | 224,719.00 |
| Dec 31, 2023 | 243,213.00 |
| Sep 30, 2023 | 623,075.00 |
| Jun 30, 2023 | 651,415.00 |
| Mar 31, 2023 | 742,635.00 |
| Dec 31, 2022 | 1.10 Mn |
| Dec 31, 2021 | 33,885.00 |